Research reveals long term benefits of Covaxin
The study, funded by the Centre's department of biotechnology has shown that T and B cell memory responses generated by Covaxin measures.
Published: 21st November 2021 10:48 AM | Last Updated: 21st November 2021 10:48 AM | A+A A-
A health official shows Covaxin dose. (File Photo| Shekhar Yadav, EPS)
NEW DELHI: A research led by the National Institute of Immunology, apart from several other government institutions, has for the first time confirmed Covaxin-induced immune memory, indicating that the COVID-19 vaccine is capable of ensuring long term protection against severe disease.
The study, funded by the Centre's department of biotechnology has shown that T and B cell memory responses generated by Covaxin measures similar to the memory responses generated by the natural infection.
The finding is significant, especially as various researches have now proven that antibodies - another marker of a vaccine's efficacy - generated after being vaccinated with Covaxin is significantly lower as compared to Covishield, the other vaccine used in India.
Covaxin is India's first fully indigenously developed COVID-19 vaccine, developed by Hyderabad-based Bharat Biotech in collaboration with the ICMR. Recently, it was granted emergency use listing by the WHO.
The latest report led by NII scientists which determined the magnitude, quality and persistence of cellular and humoral memory responses up to six months after vaccination with Covaxin, says the quantity of vaccine-induced spike and nucleoprotein antibodies is comparable to that following natural infection and the antibodies are detectable up to six months.
The RBD-specific antibodies decline in the range of 3 to 10-fold against SARS-CoV-2 variants in the order of alpha, delta, beta, with no observed impact of gamma and kappa variants. "We found that the vaccine induces memory B cells, similar to natural infection, which are impacted by virus variants in the same order as antibodies," noted the researchers.
The findings released in a pre-print for medical research establish that the inactivated vaccine Covaxin induces robust immune memory to SARS-CoV-2 and variants of concern, which persist for at least six months after vaccination.
"This study has implication for future vaccine development, guidance for use of inactivated virus vaccine, and booster immunisation," it said.
Immune memory up to six months
The findings establish that the inactivated vaccine Covaxin induces robust immune memory to SARS-CoV-2 and variants of concern, which persist for at least six months after vaccination
